Top Tweets for #ispy2
Excited to see @AnnaBarker20 kick off @PressClubDC @QuantumLeapHC #ISPY2.2 #breastcancer #adaptiveclinicaltrials #bcsm #innovate #forpatientbenefit @EITLosAngeles
Out now for #ESMO24! In #ISPY2.2, neoadjuvant Dato-DXd plus #durvalumab, sequential CT w/ or w/o targeted therapy & optional early resection, in pts w/ high-risk #BreastCancer, shows safe de-escalation in several subgroups . @DrLauraEsserman https://t.co/tPacOIXL8s
Out now for #ESMO24! In #ISPY2.2, neoadjuvant Dato-DXd, followed by sequential CT w/ or w/o targeted therapy & optional early resection after each therapy block in pts w/ high-risk #BreastCancer, was superior to SOC in a subgroup of pts. @DrLauraEsserman https://t.co/qjGsrx8Vbx
Mark Magbanua gives an excellent talk at IBCWest on ctDNA - reviewing technology and #ispy2 data @gotoPER great talk!! @ispy2 @UCSFCancer
Important Poster Alert
I-SPY2 analysis of pCR in rare breast cancer tumors including Metaplastic.
Metaplastic pCR rates 27% with chemo and higher with immune checkpoint, 34-46%.
@ASCO @A_THOMASMD @OncoAlert
#ISPY2 D-Dxd buddies!! The incredible @jane_meisel who did an phenomenal job presenting Dato alone data on Friday! She set a pretty high bar! So lucky to call her a friend! ❤️#ASCO24 #bcsm
Congratulations @Dr_RShatsky! Looking forward to your important @ISPY2trial presentation on Monday #asco24 @OncoAlert #ispy2 a major collaborative effort of a remarkable group of investigators @DrLauraEsserman @LVVPrint @UCSFCancer
#ASCO24 Anniversary dinner update. ❤️ Drinks at “After” and dinner at “Ever” If I wanted to look fancy I guess I could have worn my contacts, but honestly I’m terrible with contacts, still have work to so and after this many years of marriage who cares!!! @ER_OncDoc
Strong presentation by Kayla Switalla, BS on the benefits of clipping positive axillary nodes. #ISPY2 #ASBrS24 @ASBrS @DrJudyBoughey
🙌Hey @utswcancer @UTSWCancerBio @UTSWHemeOnc @UTSWScience
@UTSW_Pathology, don't miss our next #KomenBreastCancerForum featuring Dr. Laura van 't Veer @LVVPrint @UCSFCancer Feb 21! #ISPY2 #PrecisionOncology #TargetedTherapy #biomarkers #CancerImmunotherapy #ctDNA #BreastCancer
many congratulations to my friend and treasured colleague @RitaNandaMD! well deserved and so lucky to work with you on #ISPY2
📣 #ICYMI: @UCSDCancer researcher @Dr_RShatsky discusses the impact of cross-campus collaboration with @UCSFCancer in the success of #ISPY2 research.
@UCSF at #ASCO23: Breast Oncology Fellow Dr. Saya Jacob @UCSFHospitals and Dr. Rebecca Shatsky @Dr_RShatsky @UCSDCancer discuss their side by side I-SPY 2 posters, and the benefit of cross-campus collaboration in the success of the trial. WATCH: https://t.co/WnZipF5Ilh #ISPY2
@UCSF at #ASCO23: Breast Oncology Fellow Dr. Saya Jacob @UCSFHospitals and Dr. Rebecca Shatsky @Dr_RShatsky @UCSDCancer discuss their side by side I-SPY 2 posters, and the benefit of cross-campus collaboration in the success of the trial. WATCH: https://t.co/WnZipF5Ilh #ISPY2
What a great day at the ISPY2.2 meeting discussing the future of the trial. Wonderful to talk in person with other ISPY surgeons and medical oncologists and meet the quantum health team. @DrLauraEsserman @DrCandiceSauder @KGiridharMD #ispy2
Attending the Investigator Meeting for the amazing #ISPY2 trial! Innovative #breastcancer treatment at @cityofhope @cityofhopeoc for our patients of Southern California and beyond!
@COHMedOnc @CityofHopeSurg #BreastCancerAwarenessMonth
So proud to see @HemoncUcsf fellow @laura_huppert 🔜 @UCSFCancer faculty take Hall D1 stage presenting #ispy2 data at #ASCO22
#bcsm #UCSFProud
#Medstudent Beverly Kyalwazi @UChicagoMed presents clinical outcomes and expression-based immune signatures by race in #Ispy2 trial. Very impressive analysis and presentation by I’m sure a future leader! #bcsm #sabcs21 @SABCSSanAntonio
PHENOMENAL presentation by future Dr. @bkyalwazi MS4 😯 on outcomes by race in #ISPY2
▶️ No difference in pCR rates by self reported race
BUT...Black pts with HR+ HER2- non-pCR had higher risk of recurrence
#SABCS21 #bcsm
Great overview of adaptive trial designs at the Dutch oncology conference #NVMO2021 such as #iSPY2 in #breastcancer. Something we could consider in #GeriOnc research? Does anyone have experience with these type of designs in geriatric oncology?
The latest #ISPY2 cohort is out on @NatureComms, finding higher pCR rates w/ THP or T-DM1/P compared w/ TH (before AC)
No big clinical news - but very elegant correlatives, highlighting the wide heterogeneity of HER2+ BC and its clinical implications
https://t.co/wJsexoj8Ke
Last Seen Hashtags on Sotwe
breaking
Seen from Canada
teenagergirls
Seen from Sweden
คืนลอยกระทง
Seen from Thailand
arabsex()filter:native_video
Seen from Italy
teamcarne
shemalebandung
Seen from France
monkeyapp
Seen from Turkey
kontolcowok
Seen from Germany
Teenage nolimit*
Seen from United States
FornCaLaCarme
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.6M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.6M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.7M followers
Taylor Swift
@taylorswift13
81.5M followers
Lady Gaga
@ladygaga
73.1M followers
Virat Kohli
@imvkohli
69.9M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.9M followers
Neymar Jr
@neymarjr
62.7M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.8M followers